Toward improved effectiveness of bladder cancer immunotherapy

被引：3
作者：
Kalinski, Pawel [1 ,2 ,3 ]
Gingrich, Jeffrey R. [4 ,5 ]
机构：
[1] Univ Pittsburgh, Dept Surg, Dept Immunol, Dept Bioengn,Dept Microbiol, Pittsburgh, PA 15260 USA
[2] Univ Pittsburgh, Dept Infect Dis, Pittsburgh, PA 15260 USA
[3] Univ Pittsburgh, Hillman Canc Ctr, Inst Canc, Pittsburgh, PA 15213 USA
[4] Univ Pittsburgh, Dept Urol, Pittsburgh, PA 15260 USA
[5] Univ Pittsburgh, Inst Canc, Pittsburgh, PA 15232 USA
来源：
IMMUNOTHERAPY | 2015年 / 7卷 / 10期
基金：
美国国家卫生研究院;
关键词：
bladder cancer; checkpoint blockade; chemokines; CTL; cytokines; dendritic cells; immunotherapy; interferons; microenvironment; natural killer; NK; stroma; tumor; BACILLUS-CALMETTE-GUERIN; DENDRITIC CELLS; TLR AGONISTS; COMBINATION; MICROENVIRONMENT; RECRUITMENT; HISTORY; ALPHA; BCG;
D O I：
10.2217/imt.15.71
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
[No abstract available]
引用
收藏
页码：1039 / 1042
页数：4
相关论文
共 29 条
  • [1] The immune contexture in human tumours: impact on clinical outcome
    Fridman, Wolf Herman
    Pages, Franck
    Sautes-Fridman, Catherine
    Galon, Jerome
    [J]. NATURE REVIEWS CANCER, 2012, 12 (04) : 298 - 306
  • [2] Innate and adaptive immune cells in the tumor microenvironment
    Gajewski, Thomas F.
    Schreiber, Hans
    Fu, Yang-Xin
    [J]. NATURE IMMUNOLOGY, 2013, 14 (10) : 1014 - 1022
  • [3] The natural history of bladder carcinoma in situ after initial response to bacillus Calmette-Guerin immunotherapy
    Gofrit, Ofer N.
    Pode, Dov
    Pizov, Galina
    Zorn, Kevin C.
    Katz, Ran
    Duvdevani, Mordechi
    Shapiro, Amos
    [J]. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2009, 27 (03) : 258 - 262
  • [4] History of bacillus Calmette-Guerin and bladder cancer: An immunotherapy success story
    Herr, Harry W.
    Moralest, Alvaro
    [J]. JOURNAL OF UROLOGY, 2008, 179 (01) : 53 - 56
  • [5] TLR agonists: our best frenemy in cancer immunotherapy
    Kaczanowska, Sabina
    Joseph, Ann Mary
    Davila, Eduardo
    [J]. JOURNAL OF LEUKOCYTE BIOLOGY, 2013, 93 (06) : 847 - 863
  • [6] T-cell priming by type-1 and type-2 polarized dendritic cells: the concept of a third signal
    Kalinski, P
    Hilkens, CMU
    Wierenga, EA
    Kapsenberg, ML
    [J]. IMMUNOLOGY TODAY, 1999, 20 (12): : 561 - 567
  • [7] Consensus statement on best practice management regarding the use of intravesical immunotherapy with BCG for bladder cancer
    Kamat, Ashish M.
    Flaig, Thomas W.
    Grossman, H. Barton
    Konety, Badrinath
    Lamm, Donald
    O'Donnell, Michael A.
    Uchio, Edward
    Efstathiou, Jason A.
    Taylor, John A., III
    [J]. NATURE REVIEWS UROLOGY, 2015, 12 (04) : 225 - 235
  • [8] Immunotherapy of cancer in 2012
    Kirkwood, John M.
    Butterfield, Lisa H.
    Tarhini, Ahmad A.
    Zarour, Hassane
    Kalinski, Pawel
    Ferrone, Soldano
    [J]. CA-A CANCER JOURNAL FOR CLINICIANS, 2012, 62 (05) : 309 - 335
  • [9] Komohara Y, 2006, INT J ONCOL, V29, P1555
  • [10] TLR agonists for cancer immunotherapy: tipping the balance between the immune stimulatory and inhibitory effects
    Lu, Hailing
    [J]. FRONTIERS IN IMMUNOLOGY, 2014, 5
123